Literature DB >> 29554336

Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway.

Kiem Vu1, George R Thompson2,3, Chandler C Roe4, Jane E Sykes5, Elizabeth M Dreibe4, Shawn R Lockhart6, Wieland Meyer7, David M Engelthaler4, Angie Gelli1.   

Abstract

Cryptococcosis is an opportunistic fungal infection caused by members of the two sibling species complexes: Cryptococcus neoformans and Cryptococcus gattii. Flucytosine (5FC) is one of the most widely used antifungals against Cryptococcus spp., yet very few studies have looked at the molecular mechanisms responsible for 5FC resistance in this pathogen. In this study, we examined 11 C. gattii clinical isolates of the major molecular type VGIII based on differential 5FC susceptibility and asked whether there were genomic changes in the key genes involved in flucytosine metabolism. Susceptibility assays and sequencing analysis revealed an association between a point mutation in the cytosine deaminase gene (FCY1) and 5FC resistance in two of the studied 5FC resistant C. gattii VGIII clinical isolates, B9322 and JS5. This mutation results in the replacement of arginine for histidine at position 29 and occurs within a variable stretch of amino acids. Heterologous expression of FCY1 and spot sensitivity assays, however, demonstrated that this point mutation did not have any effect on FCY1 activities and was not responsible for 5FC resistance. Comparative sequence analysis further showed that no changes in the amino acid sequence and no genomic alterations were observed within 1 kb of the upstream and downstream sequences of either cytosine permeases (FCY2-4) or uracil phosphoribosyltransferase (FUR1) genes in 5FC resistant and 5FC susceptible C. gattii VGIII isolates. The herein obtained results suggest that the observed 5FC resistance in the isolates B9322 and JS5 is due to changes in unknown protein(s) or pathway(s) that regulate flucytosine metabolism.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29554336     DOI: 10.1093/mmy/myx135

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  5 in total

1.  5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus.

Authors:  R Blake Billmyre; Shelly Applen Clancey; Lucy X Li; Tamara L Doering; Joseph Heitman
Journal:  Nat Commun       Date:  2020-01-08       Impact factor: 14.919

Review 2.  Carrier-Mediated Drug Uptake in Fungal Pathogens.

Authors:  Mónica Galocha; Inês Vieira Costa; Miguel Cacho Teixeira
Journal:  Genes (Basel)       Date:  2020-11-09       Impact factor: 4.096

3.  Moderate levels of 5-fluorocytosine cause the emergence of high frequency resistance in cryptococci.

Authors:  Yun C Chang; Ami Khanal Lamichhane; Hongyi Cai; Peter J Walter; John E Bennett; Kyung J Kwon-Chung
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

4.  Molecular Epidemiology and Antifungal Resistance of Cryptococcus neoformans From Human Immunodeficiency Virus-Negative and Human Immunodeficiency Virus-Positive Patients in Eastern China.

Authors:  Ziyi Zhou; Chendi Zhu; Margaret Ip; Manjiao Liu; Zhaoqin Zhu; Ryon Liu; Xiaomin Li; Lingbing Zeng; Wenjuan Wu
Journal:  Front Microbiol       Date:  2022-07-05       Impact factor: 6.064

Review 5.  Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.

Authors:  Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.